<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25799" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neuroleptic Malignant Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Simon</surname>
            <given-names>Leslie V.</given-names>
          </name>
          <aff>Mayo Clinic Florida</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hashmi</surname>
            <given-names>Muhammad F.</given-names>
          </name>
          <aff>National Health Service</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Callahan</surname>
            <given-names>Avery L.</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Leslie Simon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Muhammad Hashmi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Avery Callahan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25799.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Neuroleptic malignant syndrome (NMS) is a life-threatening syndrome associated with the use of dopamine-receptor antagonist medications or with rapid withdrawal of dopaminergic medications. NMS has been associated with virtually every neuroleptic agent but is more commonly reported with the typical antipsychotics like haloperidol and fluphenazine. Classic clinical characteristics include mental status changes, fever, muscle rigidity, and autonomic instability. This activity describes the presentation of neuroleptic malignant syndrome and highlights the role of the interprofessional team in the management of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain when the diagnosis of neuroleptic malignant syndrome should be considered.</p></list-item><list-item><p>Explain how to diagnose neuroleptic malignant syndrome.</p></list-item><list-item><p>Explain the management of neuroleptic malignant syndrome.</p></list-item><list-item><p>Explore strategies to optimize care coordination among interprofessional team members to improve outcomes for patients affected by neuroleptic malignant syndrome.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25799&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25799">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25799.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Neuroleptic malignant&#x000a0;syndrome (NMS) is a life-threatening syndrome associated with the use of dopamine-receptor antagonist medications or with the rapid withdrawal of dopaminergic medications. NMS has been associated with virtually every neuroleptic agent but is more commonly reported with the typical antipsychotics like haloperidol and fluphenazine. Classic clinical characteristics include mental status changes, fever, muscle rigidity, and autonomic instability. While uncommon, NMS remains an important part of the differential diagnosis of fever and mental status changes because it requires early diagnosis and treatment to prevent significant mortality and death. Treatment involves immediately discontinuing the offending agent, aggressive supportive care to manage and prevent complications, and pharmacologic therapy in severe cases. The&#x000a0;empiric medications&#x000a0;most frequently used for refractory NMS include bromocriptine mesylate, a dopamine agonist, and dantrolene sodium, a muscle relaxant. If the syndrome is due to the rapid withdrawal of dopaminergic medication, rapid re-institution of the medication may improve symptoms.<xref ref-type="bibr" rid="article-25799.r1">[1]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="31022044">[2]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="31022041">[3]</ext-link></p>
      </sec>
      <sec id="article-25799.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The primary trigger for NMS is dopamine receptor blockade, most often due to an antipsychotic agent. NMS is usually associated with high-potency first-generation neuroleptic agents but&#x000a0;also&#x000a0;may be caused by low-potency and atypical antipsychotic agents, antiemetics, tricyclic antidepressants, and lithium. Rapid withdrawal of dopaminergic drugs, most often used to manage parkinsonian diseases, such as levodopa and amantadine,&#x000a0;also&#x000a0;may cause this syndrome. The rapid switching of one Parkinson medication to another also&#x000a0;is&#x000a0;associated with the development of NMS.<xref ref-type="bibr" rid="article-25799.r2">[4]</xref><xref ref-type="bibr" rid="article-25799.r3">[5]</xref><xref ref-type="bibr" rid="article-25799.r4">[6]</xref></p>
        <p>
<bold>Medications Associated with Neuroleptic Malignant Syndrome</bold>
</p>
        <p>Typical Neuroleptics</p>
        <list list-type="bullet">
          <list-item>
            <p>Haloperidol</p>
          </list-item>
          <list-item>
            <p>Chlorpromazine</p>
          </list-item>
          <list-item>
            <p>Fluphenazine</p>
          </list-item>
          <list-item>
            <p>Thioridazine</p>
          </list-item>
          <list-item>
            <p>Trifluordazine</p>
          </list-item>
          <list-item>
            <p>Thiothixene</p>
          </list-item>
          <list-item>
            <p>Loxapine</p>
          </list-item>
          <list-item>
            <p>Bromperidol</p>
          </list-item>
          <list-item>
            <p>Promazine</p>
          </list-item>
          <list-item>
            <p>Clopenthixol</p>
          </list-item>
        </list>
        <p>Atypical Neuroleptics</p>
        <list list-type="bullet">
          <list-item>
            <p>Olanzapine</p>
          </list-item>
          <list-item>
            <p>Clozapine</p>
          </list-item>
          <list-item>
            <p>Risperidone</p>
          </list-item>
          <list-item>
            <p>Quetiapine</p>
          </list-item>
          <list-item>
            <p>Ziprasidone</p>
          </list-item>
          <list-item>
            <p>Aripiprazole</p>
          </list-item>
          <list-item>
            <p>Zotepine</p>
          </list-item>
          <list-item>
            <p>Amisulpride</p>
          </list-item>
        </list>
        <p>Antiemetics</p>
        <list list-type="bullet">
          <list-item>
            <p>Droperidol</p>
          </list-item>
          <list-item>
            <p>Domperidone</p>
          </list-item>
          <list-item>
            <p>Metoclopramide</p>
          </list-item>
          <list-item>
            <p>Promethazine</p>
          </list-item>
          <list-item>
            <p>Prochlorperazine</p>
          </list-item>
        </list>
        <p>Others</p>
        <list list-type="bullet">
          <list-item>
            <p>Tetrabenazine</p>
          </list-item>
          <list-item>
            <p>Reserpine</p>
          </list-item>
          <list-item>
            <p>Amoxapine</p>
          </list-item>
          <list-item>
            <p>Diatrizoate</p>
          </list-item>
          <list-item>
            <p>Lithium</p>
          </list-item>
          <list-item>
            <p>Phenelzine</p>
          </list-item>
          <list-item>
            <p>Dosulepin</p>
          </list-item>
          <list-item>
            <p>Trimipramine</p>
          </list-item>
          <list-item>
            <p>Desipramine</p>
          </list-item>
        </list>
        <p>Dopaminergic Agents (withdrawal)</p>
        <list list-type="bullet">
          <list-item>
            <p>Levodopa</p>
          </list-item>
          <list-item>
            <p>Amantadine</p>
          </list-item>
          <list-item>
            <p>Tolcapone</p>
          </list-item>
          <list-item>
            <p>Dopamine agonists</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25799.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Incidence rates range from 0.01% to 3.2% of patients taking neuroleptic medications. The incidence is decreasing due to newer agents, which are less likely to cause NMS, and increased awareness of the condition. Most cases occur in young adults, but this is most likely because it is the age of first exposure to neuroleptic medications rather than an age-related risk. Men outnumber women 2:1, also related to the likelihood of exposure to the causative agent. Incidence due to the withdrawal of dopaminergic drugs is more likely in the geriatric population based on the likelihood of exposure to the inciting cause.</p>
      </sec>
      <sec id="article-25799.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathophysiology of NMS is complex and incompletely understood.&#x000a0; Most symptoms are attributed to the&#x000a0;sudden reduction in central dopaminergic activity due to a D2 receptor blockade or abrupt withdrawal of D2 receptor stimulation. This accounts for the characteristic muscle rigidity, hyperthermia, and mental status changes.&#x000a0; Other neurotransmitters are involved, and NMS has features suggestive of disruption of the sympathetic nervous system. Other theories suggest a calcium-mediated disruption&#x000a0;of the musculoskeletal system, pathophysiologically similar to malignant hyperthermia. Familial clusters of patients with NMS and genetic testing suggest&#x000a0;a&#x000a0;predisposition to the development of NMS in certain individuals.<xref ref-type="bibr" rid="article-25799.r5">[7]</xref><xref ref-type="bibr" rid="article-25799.r6">[8]</xref><xref ref-type="bibr" rid="article-25799.r7">[9]</xref></p>
      </sec>
      <sec id="article-25799.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The main risk factor for developing NMS is the initiation or increase in the dosage of neuroleptic medication. High-potency and long-aging neuromuscular depot forms carry the greatest risk. The concurrent use of multiple neuroleptic agents or lithium also increases the risk. Abrupt withdrawal of dopaminergic agents is a less common but important cause of NMS. Symptoms of NMS develop over one to three days and include distinctive clinical features: fever, muscle rigidity, mental status changes, and autonomic rigidity.</p>
        <p>The DSM-V criteria for diagnosing NMS are as follows:</p>
        <p>
<bold>Major Criteria (all required)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Exposure to dopamine-blocking agent</p>
          </list-item>
          <list-item>
            <p>Severe muscle rigidity</p>
          </list-item>
          <list-item>
            <p>Fever</p>
          </list-item>
        </list>
        <p>
<bold>Other Criteria (at least two required)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Diaphoresis</p>
          </list-item>
          <list-item>
            <p>Dysphagia</p>
          </list-item>
          <list-item>
            <p>Tremor</p>
          </list-item>
          <list-item>
            <p>Incontinence</p>
          </list-item>
          <list-item>
            <p>Altered level of consciousness</p>
          </list-item>
          <list-item>
            <p>Mutism</p>
          </list-item>
          <list-item>
            <p>Tachycardia</p>
          </list-item>
          <list-item>
            <p>Elevated or labile blood pressure</p>
          </list-item>
          <list-item>
            <p>Leukocytosis</p>
          </list-item>
          <list-item>
            <p>Elevated creatine phosphokinase</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25799.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Evaluation should include a comprehensive metabolic panel including electrolytes and serum creatinine, creatine phosphokinase level, urinalysis for myoglobinuria, and arterial or venous blood gas to screen for metabolic acidosis. Diagnosis can be made clinically, but supporting lab work is usually consistent with rhabdomyolysis with an elevated CK and acutely declining renal function. The elevated CK can be profound and typically correlates with disease severity. Leukocytosis is common with white blood cell counts ranging from 10,00 to 40,000 mm3 with a left shift. Transaminases may also be mildly elevated. In patients where the diagnosis is less clear, neuroimaging and lumbar puncture may be necessary to exclude structural and infectious diagnosis from the differential.&#x000a0;Additional laboratory testing&#x000a0;such as a lithium level and screening for drugs of abuse may be helpful in selected cases.</p>
      </sec>
      <sec id="article-25799.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>NMS is a neurologic emergency, and delays in diagnosis and treatment can lead to significant morbidity or death. Discontinuing the offending agent is paramount, followed by supportive therapy. <xref ref-type="bibr" rid="article-25799.r8">[10]</xref><xref ref-type="bibr" rid="article-25799.r9">[11]</xref>&#x000a0;This includes aggressive cooling and correction of volume deficits and any electrolyte imbalances. Patients are prone to cardiac dysrhythmias and respiratory failure due to chest wall rigidity. Treat with antiarrhythmic agents and mechanical ventilation as needed. More severe cases are managed with empiric pharmacologic therapy. Meta-analyses and case reports suggest that these may shorten the course and reduce morbidity and mortality. Bromocriptine, a dopamine agonist, given orally or via a gastric tube, is used to reverse the hypodopaminergic state.&#x000a0;Dantrolene, a muscle relaxant may be administered intravenously or orally in less severe cases.&#x000a0; Benzodiazepines&#x000a0;also&#x000a0;may be useful in controlling agitation. If the syndrome is due to a&#x000a0;rapid withdrawal of dopaminergic agents, restarting the drug may reduce symptoms. Electroconvulsive therapy&#x000a0;also&#x000a0;has been reportedly effective in refractory cases. Patients should be admitted for close monitoring in an intensive care unit setting.<xref ref-type="bibr" rid="article-25799.r10">[12]</xref></p>
      </sec>
      <sec id="article-25799.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>NMS is one of a group of drug-related acute dysautonomias with common features of fever, rigidity, and autonomic dysfunction. Serotonin syndrome has similar features to NMS and is most easily distinguished by the causative agent, most frequently the serotonin-specific reuptake inhibitors. Hyperthermia and muscle rigidity are usually less severe with serotonin syndrome than with NMS; additionally, serotonin syndrome is more commonly associated with gastrointestinal symptoms, hyperreflexia, and myoclonus. Malignant hyperthermia is almost clinically indistinguishable from NMS, but the history of exposure to depolarizing muscle relaxants, most commonly succinylcholine, or inhaled anesthetic agents make the distinction clear in most cases. Malignant catatonia (MC) may present with fever, rigidity, akinesia, and altered mental status. It is important to distinguish from NMS because&#x000a0;malignant catatonia&#x000a0;shows robust responsiveness--reports reveal a full recovery in up to 80% of patients--with rapid initiation of benzodiazepines and electroconvulsive therapy.<xref ref-type="bibr" rid="article-25799.r11">[13]</xref>&#x000a0;Distinguishing features of malignant catatonic include increased positive symptoms as compared to NMS and a behavioral prodrome of automatisms, agitation, or psychosis.</p>
        <p>Multiple other medical conditions can mimic NMS,&#x000a0;making&#x000a0;it easy to misdiagnose.&#x000a0;The most common mimics are central nervous system (CNS) infections such as meningitis or encephalitis, heatstroke, agitated delirium, toxic encephalopathies, withdrawal syndromes, metabolic emergencies, and nonconvulsive status epilepticus.</p>
        <p>Acute encephalitis, meningitis, or brain abscess must be excluded in patients presenting with fever and mental status changes to avoid delay in treatment of CNS infection.&#x000a0;This involves lumbar puncture for cerebrospinal fluid analysis and neuroimaging in certain cases. Patients on antipsychotic drugs are predisposed to heat-related illnesses, which may&#x000a0;resemble NMS. Acute intoxication with many recreational drugs such as cocaine, MDMA, amphetamines, methamphetamines, and phencyclidine may have similar features. Abuse of recreational drugs may occur in the setting of medical therapy with antipsychotics making the clinical picture ambiguous. Several withdrawal syndromes may present with features similar to NMS, especially withdrawal from muscle relaxants; the emergence of a withdrawal from an agent like baclofen is best managed by reinitiation therapy or with benzodiazepines. Alcohol and benzodiazepine withdrawal&#x000a0;also share features with NMS as do the withdrawal syndromes of other sedatives and hypnotics. Thyrotoxicosis and pheochromocytoma&#x000a0;also have overlapping&#x000a0;manifestations in common with NMS.</p>
      </sec>
      <sec id="article-25799.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Early mortality reports were&#x000a0;greater than 30% for NMS; however, increased awareness, earlier detection,&#x000a0;and better supportive care have reduced mortality to less than 10%. With early recognition and aggressive treatment, most patients will fully recover in 2&#x000a0;to 14 days. Delayed treatment may result in significant morbidity such as residual catatonia, parkinsonism, renal, or cardiopulmonary complications. When fatal, deaths are usually due to cardiac arrhythmias, disseminated intravascular coagulation, respiratory failure, or renal failure. Many patients may be successfully restarted on neuroleptic medications, but some will develop recurrent symptoms. Guidelines for re-initiation of neuroleptic therapy recommend waiting at least two weeks after resolution of symptoms, using lower-potency agents, starting with low doses and slowly titrating to effect, and avoiding lithium in conjunction with neuroleptics. Patients should be instructed to avoid dehydration and should be carefully monitored for any symptoms of recurrent NMS.</p>
      </sec>
      <sec id="article-25799.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>NMS is a medical emergency that is best managed by an interprofessional team. These patients are ideally managed in the ICU with very close nursing monitoring and reporting to the team. A pharmacist trained in toxicology and a toxicologist should be involved in assisting with treatment and management decisions. The key is hydration and supportive therapy. There is no specific drug to reverse this disorder. Anecdotal reports on dantrolene continue to appear but a few case studies indicate that the drug may neither be effective or safe.<xref ref-type="bibr" rid="article-25799.r12">[14]</xref></p>
        <p>For most patients in whom the offending drug is discontinued, the prognosis is good. An interprofessional approach to the education of the family, monitoring, and treatment by clinicians, nurses, and pharmacists will provide the best outcomes. [Levell 5]</p>
      </sec>
      <sec id="article-25799.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25799&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25799">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/neuroleptic-malignant-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25799">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25799/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25799">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25799.s13">
        <title>References</title>
        <ref id="article-25799.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Duma</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Fung</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced movement disorders.</article-title>
            <source>Aust Prescr</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>56</fpage>
            <page-range>56-61</page-range>
            <pub-id pub-id-type="pmid">31048939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ott</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Werneke</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>A Mixed Presentation of Serotonin Syndrome Versus Neuroleptic Malignant Syndrome in a 12-Year-Old Boy.</article-title>
            <source>Pediatr Emerg Care</source>
            <year>2019</year>
            <month>May</month>
            <volume>35</volume>
            <issue>5</issue>
            <fpage>e98</fpage>
            <pub-id pub-id-type="pmid">30964850</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Rensburg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Decloedt</surname>
                <given-names>EH</given-names>
              </name>
            </person-group>
            <article-title>An Approach to the Pharmacotherapy of Neuroleptic Malignant Syndrome.</article-title>
            <source>Psychopharmacol Bull</source>
            <year>2019</year>
            <month>Feb</month>
            <day>15</day>
            <volume>49</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-91</page-range>
            <pub-id pub-id-type="pmid">30858642</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Salik</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Marwaha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Electroconvulsive Therapy</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>19</day>
            <pub-id pub-id-type="pmid">30855854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Manabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yanagi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takagi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome as part of an akinetic crisis associated with sepsis in a patient with Lewy body disease.</article-title>
            <source>BMJ Case Rep</source>
            <year>2019</year>
            <month>Feb</month>
            <day>28</day>
            <volume>12</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">30824461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jamshidi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The hot patient: acute drug-induced hyperthermia.</article-title>
            <source>Aust Prescr</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>24</fpage>
            <page-range>24-28</page-range>
            <pub-id pub-id-type="pmid">30765906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kane</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Correll</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Delva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gopal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Savitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Low Incidence of Neuroleptic Malignant Syndrome Associated With Paliperidone Palmitate Long-Acting Injectable: A Database Report and Case Study.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2019</year>
            <season>Mar/Apr</season>
            <volume>39</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-182</page-range>
            <pub-id pub-id-type="pmid">30811377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grover</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sathpathy</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Parkinsonism-hyperpyrexia syndrome: A case report and review of literature.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>499</fpage>
            <page-range>499-503</page-range>
            <pub-id pub-id-type="pmid">30581218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ratto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Joyner</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <chapter-title>Dantrolene</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30571019</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaliora</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Zervas</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Papadimitriou</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>[Electroconvulsive therapy: 80 years of use in psychiatry].</article-title>
            <source>Psychiatriki</source>
            <year>2018</year>
            <season>Oct-Dec</season>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>291</fpage>
            <page-range>291-302</page-range>
            <pub-id pub-id-type="pmid">30814039</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Krzeminski</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hazeghazam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bandlamuri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Malignant Catatonia Warrants Early Psychiatric-Critical Care Collaborative Management: Two Cases and Literature Review.</article-title>
            <source>Case Rep Crit Care</source>
            <year>2017</year>
            <volume>2017</volume>
            <fpage>1951965</fpage>
            <pub-id pub-id-type="pmid">28250995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25799.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>VI</given-names>
              </name>
              <name>
                <surname>Larach</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Mayes</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shukry</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Theroux</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Watt</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Consensus Statement of the Malignant Hyperthermia Association of the United States on Unresolved Clinical Questions Concerning the Management of Patients With Malignant Hyperthermia.</article-title>
            <source>Anesth Analg</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>128</volume>
            <issue>4</issue>
            <fpage>652</fpage>
            <page-range>652-659</page-range>
            <pub-id pub-id-type="pmid">30768455</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
